You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
RS 79948 hydrochloride
α2-adrenoreceptor antagonist (Kd values are; 0.18, 0.19 and 0.42 nM for α2B α2C and α2A, respectively in rat).
Sold with the permission of Roche Bioscience
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble to 25 mM in water|
References are publications that support the biological activity of the product.
Clark et al (1989) (8aα,12aα,13aα)-5,8,8a,9,10,11,12,12a,13,13a-Decahydro-3-methoxy-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]-naphthyridine, a potent and highly selective α2-adrenoceptor antagonist. J. Med. Chem. 32 2034 PMID: 2570150
Hume et al (1996) Evaluation in rat of RS-79948-197 as a potential PET ligand for central α2-adrenoceptors. Eur.J.Pharmacol. 317 67 PMID: 8982721
Uhlen et al (1998) [3H]RS79948-197 binding to rat, guinea pig and pig α2A-, α2B and α2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur.J.Pharmacol. 343 93 PMID: 9551719
If you know of a relevant reference for RS 79948 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: RS 79948 hydrochloride, RS 79948 hydrochloride supplier, Potent, selective, α2-adrenoceptor, alpha2-adrenoceptor, α2-Adrenergic, alpha2-Adrenergic, a2-adrenoceptor, a2-adrenergic, antagonists, Receptors, RS79948, hydrochloride, Adrenergic, Alpha-2, 0987, Tocris Bioscience
4 Citations for RS 79948 hydrochloride
Citations are publications that use Tocris products. Selected citations for RS 79948 hydrochloride include:
Qu et al (2019) Structural Basis of the Diversity of Adrenergic Receptors. Cell Reports 29 2929 PMID: 31801060
Chen et al (2019) Molecular Mechanism for Ligand Recognition and Subtype Selectivity of α2C Adrenergic Receptor. Cell Reports 29 2936 PMID: 31801061
Hirono (2017) Monoaminergic modulation of GABAergic transmission onto cerebellar globular cells. Neuropharmacology 118 79 PMID: 28300552
Zacharia et al (2013) High vascular tone of mouse femoral arteries in vivo is determined by sympathetic nerve activity via α1A- and α1D-adrenoceptor subtypes. PLoS One 8 e65969 PMID: 23776582
Do you know of a great paper that uses RS 79948 hydrochloride from Tocris? Please let us know.
Reviews for RS 79948 hydrochloride
There are currently no reviews for this product. Be the first to review RS 79948 hydrochloride and earn rewards!
Have you used RS 79948 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.